8-K: Sanara MedTech Reports Strong 2025 Sales, Reaffirms 2026 Guidance

Sanara MedTech Inc. announced robust fourth quarter and full year 2025 financial results, with net revenue exceeding $100 million, and reaffirmed its 2026 financial guidance.

Summary

• Net revenue for the fourth quarter of 2025 increased 5% to $27.5 million, compared to $26.3 million in the fourth quarter of 2024. Excluding extraordinary BIASURGE sales in Q4 2024, net revenue increased 13% year-over-year.
• Full year 2025 net revenue increased 19% to $103.1 million, compared to $86.7 million in 2024. Excluding extraordinary BIASURGE sales in Q4 2024, net revenue increased 22% year-over-year.
• Net loss from continuing operations for the fourth quarter of 2025 was $1.1 million, compared to net income from continuing operations of $0.9 million in the fourth quarter of 2024.
• Net loss from continuing operations for the full year 2025 was $0.4 million, a significant improvement from a net loss of $1.9 million in 2024.
• Adjusted EBITDA for the fourth quarter of 2025 was $4.7 million, up from $4.1 million in the fourth quarter of 2024.
• Adjusted EBITDA for the full year 2025 was $17.0 million, nearly doubling from $9.1 million in 2024.
• Net cash provided by operating activities for the full year 2025 was $6.8 million, a substantial improvement from $23.8 thousand of net cash used in operating activities in 2024.
• The company reaffirmed its full year 2026 net revenue guidance to range from $116 million to $121 million, representing growth of approximately 13% to 17% over 2025.
• The strategic realignment classified Tissue Health Plus (THP) operations as discontinued, resulting in a noncash asset impairment charge of $26.5 million in the full year 2025, contributing to a total net loss of $37.6 million for the year.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively due to strong revenue growth, significant improvement in Adjusted EBITDA and cash flow from operations, and strategic market access wins, despite an increase in net loss primarily driven by non-cash impairment charges related to discontinued operations.

Positives

• Achieved first full year of net revenue in excess of $100 million, reaching $103.1 million with 19% year-over-year growth (22% excluding extraordinary sales).
• Adjusted EBITDA for the full year 2025 significantly increased to $17.0 million, nearly doubling from $9.1 million in 2024.
• Generated $6.8 million of cash from operating activities in 2025, a strong turnaround from net cash used in 2024.
• Gross margin improved to 93% in Q4 2025 from 91% in Q4 2024, driven by increased soft tissue repair product sales and lower manufacturing costs.
• BIASURGE Advanced Surgical Solution received an Innovative Technology contract from Vizient Inc., providing access to Vizient's extensive network of healthcare facility customers at contracted pricing.
• A peer-reviewed study published in the Journal of Medical Economics demonstrated cost savings and improved health outcomes with CellerateRX Surgical Powder in high-risk spinal surgery patients.

Negatives

• Net loss from continuing operations for Q4 2025 was $1.1 million, a decline from net income of $0.9 million in Q4 2024.
• Total net loss for the full year 2025 was $37.6 million, significantly higher than $9.9 million in 2024, primarily due to a $26.5 million noncash asset impairment charge related to discontinued operations (THP).
• Operating expenses increased 13% in Q4 2025, partly due to a $1.8 million noncash asset impairment charge related to certain IP assets.
• Long-term debt increased to $46.0 million as of December 31, 2025, from $30.7 million as of December 31, 2024.
• Interest expense for the full year 2025 increased to $6.76 million from $3.13 million in 2024.

Risks

• Uncertainties associated with the development and process for obtaining regulatory approval for new products, such as the OsStic Synthetic Injectable Structural Bio-Adhesive.
• Risks related to the extent of product demand, market, and customer acceptance for new and existing products.
• Potential impact of economic conditions, competition, and pricing pressures in the surgical market.
• Uncertainties associated with the ability to consummate and integrate future acquisitions.
• Reliance on the ability to continue developing distributor relationships and expanding into new healthcare facilities and markets.

Future Outlook

The company reaffirmed its full year 2026 net revenue guidance, expecting a range of $116 million to $121 million, representing 13% to 17% growth over 2025. Management is focused on building on recent progress, expanding market access, executing its commercial strategy, and increasing R&D expenditure to support existing products and pipeline, aiming for sustainable long-term growth, strong cash generation, and profitability. The company also plans to introduce the OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. commercial market in the first quarter of 2027, following anticipated FDA clearance.

Management Comments

• "We are pleased to deliver strong sales performance in 2025, achieving our first full year of net revenue in excess of $100 million, with 19% growth year-over-year."
• "Our sales performance reflected impressive commercial execution by our field sales team, who continued to develop our distributor relationships, while educating potential surgeon customers in both new and existing healthcare facilities."
• "Importantly, we complemented our full year net revenue growth by expanding our gross margins and demonstrating operating leverage, enabling Sanara to achieve significant year-over-year improvements in our profitability profile, while generating $6.8 million of cash from operating activities."
• "Sanara enters 2026 as a pure play surgical business with a singular focus on the surgical operating setting, a proven commercial strategy, and a compelling margin profile."
• "We are reaffirming our net revenue guidance today, which calls for full year net revenue growth of 13% to 17% year-over-year in 2026, and look forward to delivering against these expectations."
• "Through focused execution and targeted capital allocation, we believe we will continue to position Sanara for sustainable long-term growth in the surgical market, strong cash generation and profitability over the coming years."

Industry Context

StockSavvy.ai notes that Sanara MedTech's strategic shift to a pure-play surgical business aligns with a broader industry trend towards specialization and focus on high-margin segments within the medical technology sector. The Innovative Technology contract with Vizient Inc. for BIASURGE is a significant market access win, potentially accelerating adoption within Vizient's extensive network, similar to how other medical device companies leverage Group Purchasing Organizations (GPOs) for market penetration. The planned Q1 2027 launch of OsStic for peri-articular fractures positions Sanara to address a specific, high-volume orthopedic need, potentially competing with existing fixation methods from larger players like Stryker or DePuy Synthes.

Comparison to Industry Standards

• Sanara's 19% net revenue growth for 2025 (22% adjusted) is robust, potentially outperforming the average growth rate for the broader medical device market, which typically ranges from 5-8% annually, though specialized surgical segments can see higher growth.
• A gross margin of 93% in Q4 2025 is exceptionally strong, indicating premium pricing power and/or efficient manufacturing, comparing favorably to many medical device companies where gross margins often range from 60-80%.
• The significant increase in Adjusted EBITDA from $9.1 million to $17.0 million year-over-year demonstrates strong operational leverage, a key indicator of efficiency often sought by investors when comparing against peers like Integra LifeSciences or Organogenesis.
• The shift from net cash used in operating activities to $6.8 million provided by operating activities in 2025 is a positive indicator of financial health and self-sufficiency, a metric closely watched by analysts assessing companies in growth phases.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth, improved profitability metrics (Adjusted EBITDA, cash from operations), and reaffirmed positive guidance. Negative impact from increased net loss due to impairment charges and increased debt.
• Customers (Hospitals/Surgical Centers): Benefit from expanded product offerings (e.g., BIASURGE via Vizient contract) and clinically validated solutions (CellerateRX Surgical study).
• Employees: Continued commercial execution and R&D investment suggest stable to growing employment opportunities.
• Creditors: Increased long-term debt but also improved cash flow from operations, which could enhance debt servicing capacity.

Next Steps

• Continue to develop distributor relationships and educate surgeon customers in both new and existing healthcare facilities.
• Execute commercial strategy to build on recent progress and expanded market access.
• Increase R&D expenditure to support existing products and pipeline.
• Introduce OsStic Synthetic Injectable Structural Bio-Adhesive to the U.S. commercial market in the first quarter of 2027, following anticipated FDA clearance.
• Deliver against reaffirmed full year 2026 net revenue guidance of $116 million to $121 million.

Key Dates

Recommendation

The company demonstrated strong operational performance in 2025 with significant revenue growth and a near doubling of Adjusted EBITDA, coupled with a positive shift to cash generation from operations. The strategic focus on the surgical market, coupled with key market access wins like the Vizient contract and a promising pipeline (OsStic), positions Sanara for continued growth. While the reported net loss increased due to non-cash impairment charges from discontinued operations, the underlying surgical business shows robust health and positive future guidance, making it an attractive 'buy' for long-term investors.

Keywords

Sanara MedTech, SMTI, Financial Results, Q4 2025, Full Year 2025, Surgical Market, Medical Technology, BIASURGE, CellerateRX Surgical, Adjusted EBITDA, Net Revenue, Financial Guidance, OsStic, Vizient, Healthcare, Wound Care, Bone Fusion, Soft Tissue Repair